Camp4 Therapeutics Corp (CAMP)

Current Report Filed: 2026-05-14

Key Insights

CAMP4 announced positive preclinical data for CMP-002 showing improved seizure threshold and severity in a SYNGAP1-related disorder model, demonstrating therapeutic potential in a rare genetic neurological disorder with limited treatment options.
The company is actively advancing its pipeline through data presentations and investor communications, updating corporate materials to highlight clinical progress which may support future funding or partnership discussions.
This is a Regulation FD disclosure of non-material information (preclinical data presentation), indicating the company is in early-to-mid stage development with no immediate revenue impact, typical for clinical-stage biotech companies.

Current Report Filed: 2026-05-07

Key Insights

Camp4 Therapeutics released Q1 2026 financial results on May 7, 2026, indicating the company is actively communicating operational and financial performance to shareholders.
The filing is a routine earnings announcement with no indication of material events, acquisitions, leadership changes, or significant agreements that would materially impact the company's strategic direction.
As an emerging growth company, Camp4 has elected standard compliance timelines for accounting standards, suggesting the company is utilizing available regulatory flexibility typical for earlier-stage public biotech firms.

Quarterly Report Filed: 2026-05-07

Key Insights

The filing is heavily redacted and contains primarily structural XBRL metadata without substantive financial data, making it impossible to assess revenue trends, operating performance, or financial health for Q1 2026.
Multiple references to collaborative arrangements (Children's Medical Center Corporation, Whitehead Institute, BioMarin Pharmaceutical, GSK) and licensing agreements suggest ongoing research partnerships, though specific financial impacts and milestone achievements are not disclosed in the available content.
Recent financing activities including private placements (September 2025), underwritten offering (December 2025), and shelf registration statement (November 2025) indicate the company is actively raising capital, though cash burn rate and runway cannot be determined from the truncated filing.

Insider Trading Filed: 2026-04-03

Key Insights

Michael F. MacLean, a director of Camp4 Therapeutics Corp, has acquired 56,000 stock options with an exercise price of $4.46 and a 10-year expiration date.
The stock options vest in equal monthly installments over a period of three years, indicating a long-term commitment to the company.
Insider ownership and alignment with shareholders is a positive sign for the company's future prospects.

Insider Trading Filed: 2026-04-03

Key Insights

Josh Mandel-Brehm, the CEO and Director of Camp4 Therapeutics Corp, has been granted a stock option to acquire 580,000 shares of the company's common stock, vesting over a 4-year period.
The exercise price of the stock option is $4.46 per share, which may suggest the company's stock price is currently trading at that level or above.
The timely filing of this Form 4 indicates the company's commitment to transparency and compliance with regulatory reporting requirements.

Insider Trading Filed: 2026-04-03

Key Insights

Kelly Gold, the Chief Financial Officer of Camp4 Therapeutics Corp, acquired 215,000 stock options on April 1, 2026 with an exercise price of $4.46 and a 10-year expiration date.
The stock option grant vests in equal monthly installments over a period of four years, indicating a long-term commitment from the CFO to the company.
Insider buying of this magnitude, representing a sizable portion of the CFO's compensation, suggests the executive team's confidence in the company's future prospects.

Insider Trading Filed: 2026-04-03

Key Insights

Yuri Maricich, the Chief Medical Officer of Camp4 Therapeutics Corp (CAMP), has acquired 215,000 stock options with an exercise price of $4.46 on April 1, 2026, indicating the company's confidence in its future growth and management's alignment with shareholder interests.
The options vest over a four-year period, suggesting a long-term commitment from the executive and the company's focus on building sustainable value.
Insider buying is generally seen as a positive signal, as executives are typically well-informed about the company's prospects and willing to invest in its future.

Insider Trading Filed: 2026-04-03

Key Insights

Daniel Tardiff, the Chief Scientific Officer, acquired 170,000 stock options with an exercise price of $4.46 and a 10-year expiration date. This suggests he is confident in the company's long-term prospects.
The options vest over 4 years, aligning Tardiff's interests with shareholders and incentivizing him to drive the company's scientific and operational success.
Insider buying is a positive signal, as it indicates Tardiff's belief in the company's future growth potential and willingness to invest his own capital.

Current Report Filed: 2026-03-24

Key Insights

Camp4 Therapeutics has appointed Michael MacLean, an experienced biotechnology finance executive, as a new director on the Board.
MacLean has over 35 years of financial leadership experience in the biotech and life sciences industry, with expertise in public company reporting, capital markets, internal controls, and corporate governance.
The company has updated its non-employee director compensation policy to grant 56,000 stock options to directors appointed after the effective date, including MacLean.

Current Report Filed: 2026-03-05

Key Insights

CAMP4 Therapeutics Corporation reported its 2025 financial results, indicating that the company continues to make progress in its drug development pipeline.
The company has updated its corporate presentation, providing investors with the latest information on its business and pipeline.
As an emerging growth company, CAMP4 Therapeutics has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Annual Report Filed: 2026-03-05

Key Insights

Camp4 Therapeutics Corp is a biopharmaceutical company focused on developing novel antisense oligonucleotide therapeutics. The company has several key collaborations in place, including with Fulcrum Therapeutics, Eli Lilly, and BioMarin Pharmaceutical.
The company's financial position appears stable, with $XX million in cash and cash equivalents as of December 31, 2025. However, it continues to incur significant R&D and G&A expenses as it advances its pipeline.
Camp4 Therapeutics is planning to initiate a Phase 2 clinical trial for its lead product candidate in 2026, which represents a key milestone for the company.

Current Report Filed: 2026-01-09

Key Insights

Camp4 Therapeutics Corporation, a Delaware-based biopharmaceutical company, has updated its corporate presentation, providing investors with a summary of its business activities.
The company's stock trades on the Nasdaq Global Market under the ticker symbol CAMP, indicating it is an emerging growth company that has elected not to use the extended transition period for complying with new or revised financial accounting standards.
The updated presentation is available on the company's investor relations website, suggesting the management team is actively engaging with the investment community to provide updates on the company's progress.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information